Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02305979 · ClinicalTrials.gov registry record
Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies
A clinical trial of Lymphoma and Leukemia, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 61
- Enrollment target
- 1
- Study location
NCT02305979 is a study of Lymphoma and Leukemia that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 61 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02305979, a study of Lymphoma and Leukemia, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this project is to assess the efficacy of loratadine in decreasing the incidence and severity of bone pain following G-CSF administration in patients with hematologic malignancies, patients undergoing mobilization of hematopoietic progenitor cells, and patients who have undergone an autologous hematopoietic cell transplant. This is a different patient population than those being assessed in current clinical trials.
Interventions
- DRUG Loratadine
Study Locations (1)
North Carolina
- Comprehensive Cancer Center of Wake Forest University - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02305979
The ClinicalTrials.gov registry entry for NCT02305979 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (87% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Loratadine is the first listed.
NCT02305979 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02305979 about?
NCT02305979 is a clinical study titled "Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies". The purpose of this project is to assess the efficacy of loratadine in decreasing the incidence and severity of bone pain following G-CSF administration in patients with hematologic malignancies, patients undergoing mobilization of hematopoietic progenitor cells, and patients who have undergone an a...
What is the current status of trial NCT02305979?
This trial is currently completed. The enrollment target is 61 participants. The study started on 2014-12. Estimated completion is 2017-09.
What conditions does trial NCT02305979 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia.
What interventions are being tested in trial NCT02305979?
The interventions under investigation include: Loratadine (DRUG).
Who is sponsoring clinical trial NCT02305979?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02305979 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
RECRUITING · Early Phase 1
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.